{"summary": "study compared efficacy and safety of inosine pranobex versus placebo in subjects with clinically diagnosed influenza-like illness. subgroup analyses evaluated efficacy of inosine pranobex compared to placebo in otherwise healthy subjects less than 50 years of age. effect of body mass index (BMI) was evaluated in subjects less than 50 years of age. inosine pranobex was generally well tolerated, and no deaths were reported. results indicate the safety of inosine pranobex for the treatment of subjects with confirmed acute respiratory viral infections."}